TW240217B - - Google Patents

Info

Publication number
TW240217B
TW240217B TW082111006A TW82111006A TW240217B TW 240217 B TW240217 B TW 240217B TW 082111006 A TW082111006 A TW 082111006A TW 82111006 A TW82111006 A TW 82111006A TW 240217 B TW240217 B TW 240217B
Authority
TW
Taiwan
Application number
TW082111006A
Other languages
Chinese (zh)
Original Assignee
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB929227125A external-priority patent/GB9227125D0/en
Priority claimed from GB929227116A external-priority patent/GB9227116D0/en
Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd
Application granted granted Critical
Publication of TW240217B publication Critical patent/TW240217B/zh

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D231/00Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/12Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D233/00Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/64Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms, e.g. histidine
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D263/00Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/02Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
    • C07D263/08Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D263/10Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D263/00Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/02Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
    • C07D263/30Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D263/32Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D277/00Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/22Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C07D277/30Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D327/00Heterocyclic compounds containing rings having oxygen and sulfur atoms as the only ring hetero atoms
    • C07D327/02Heterocyclic compounds containing rings having oxygen and sulfur atoms as the only ring hetero atoms one oxygen atom and one sulfur atom
    • C07D327/04Five-membered rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
TW082111006A 1992-12-30 1993-12-27 TW240217B (enrdf_load_stackoverflow)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB929227125A GB9227125D0 (en) 1992-12-30 1992-12-30 Chemical compounds
GB929227116A GB9227116D0 (en) 1992-12-30 1992-12-30 Chemical compounds

Publications (1)

Publication Number Publication Date
TW240217B true TW240217B (enrdf_load_stackoverflow) 1995-02-11

Family

ID=26302242

Family Applications (1)

Application Number Title Priority Date Filing Date
TW082111006A TW240217B (enrdf_load_stackoverflow) 1992-12-30 1993-12-27

Country Status (5)

Country Link
CN (1) CN1094037A (enrdf_load_stackoverflow)
AU (1) AU5815594A (enrdf_load_stackoverflow)
IL (1) IL108218A0 (enrdf_load_stackoverflow)
TW (1) TW240217B (enrdf_load_stackoverflow)
WO (1) WO1994015920A1 (enrdf_load_stackoverflow)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH09506101A (ja) * 1993-12-07 1997-06-17 スミスクライン・ビーチャム・パブリック・リミテッド・カンパニー 5ht1d拮抗薬として有用な複素環式ビフェニリルアミド類
GB9507203D0 (en) * 1995-04-07 1995-05-31 Smithkline Beecham Plc Novel compounds
FR2740134B1 (fr) * 1995-10-18 1998-01-09 Pf Medicament Derives d'amines cycliques d'aryl-piperazines, leur preparation et les compositions pharmaceutiques les contenant
FR2744450A1 (fr) * 1996-02-02 1997-08-08 Pf Medicament Nouvelles naphtylpiperazines derivees de cycloazanes substitues, ainsi que leur procede de preparation, les compositions pharmaceutiques et leur utilisation comme medicaments
FR2744449B1 (fr) * 1996-02-02 1998-04-24 Pf Medicament Nouvelles piperazines aromatiques derivees de cycloazanes substitues, ainsi que leur procede de preparation, les compositions pharmaceutiques et leur utilisation comme medicaments
EP0946551A2 (en) * 1996-12-19 1999-10-06 Smithkline Beecham Plc N-piperazin-1-ylphenyl-benzamide derivatives
EP1102755B1 (en) 1998-08-07 2006-01-04 Chiron Corporation Substituted isoxazole derivatives as estrogen receptor modulators
SE9904723D0 (sv) * 1999-12-22 1999-12-22 Carlsson A Research Ab New modulators of dopamine neurotransmission II
PE20020506A1 (es) 2000-08-22 2002-07-09 Glaxo Group Ltd Derivados de pirazol fusionados como inhibidores de la proteina cinasa
GB0124933D0 (en) 2001-10-17 2001-12-05 Glaxo Group Ltd Chemical compounds
GB0124936D0 (en) 2001-10-17 2001-12-05 Glaxo Group Ltd Chemical compounds
GB0124934D0 (en) 2001-10-17 2001-12-05 Glaxo Group Ltd Chemical compounds
GB0124938D0 (en) 2001-10-17 2001-12-05 Glaxo Group Ltd Chemical compounds
GB0124939D0 (en) 2001-10-17 2001-12-05 Glaxo Group Ltd Chemical compounds
GB0124931D0 (en) 2001-10-17 2001-12-05 Glaxo Group Ltd Chemical compounds
GB0124941D0 (en) 2001-10-17 2001-12-05 Glaxo Group Ltd Chemical compounds
MXPA04007838A (es) 2002-02-12 2004-10-15 Smithkline Beecham Corp Derivados de nicotamida utiles como inhibidores p38.
GB0209891D0 (en) * 2002-04-30 2002-06-05 Glaxo Group Ltd Novel compounds
GB0217757D0 (en) 2002-07-31 2002-09-11 Glaxo Group Ltd Novel compounds
GB0308186D0 (en) 2003-04-09 2003-05-14 Smithkline Beecham Corp Novel compounds
GB0308185D0 (en) 2003-04-09 2003-05-14 Smithkline Beecham Corp Novel compounds
GB0308201D0 (en) 2003-04-09 2003-05-14 Smithkline Beecham Corp Novel compounds
GB0318814D0 (en) 2003-08-11 2003-09-10 Smithkline Beecham Corp Novel compounds
JO3598B1 (ar) 2006-10-10 2020-07-05 Infinity Discovery Inc الاحماض والاسترات البورونية كمثبطات اميد هيدروليز الحامض الدهني
US7737149B2 (en) 2006-12-21 2010-06-15 Astrazeneca Ab N-[5-[2-(3,5-dimethoxyphenyl)ethyl]-2H-pyrazol-3-yl]-4-(3,5-dimethylpiperazin-1-yl)benzamide and salts thereof
EP2282742A1 (en) 2008-04-09 2011-02-16 Infinity Pharmaceuticals, Inc. Inhibitors of fatty acid amide hydrolase
MX361011B (es) 2010-02-03 2018-11-26 Infinity Pharmaceuticals Inc Inhibidores de amida hidrolasa de ácido graso.
RS54870B1 (sr) * 2010-10-30 2016-10-31 Lupin Ltd Derivati oksazolina i izoksazolina kao crac modulatori
US20140179712A1 (en) 2012-12-21 2014-06-26 Astrazeneca Ab Pharmaceutical formulation of n-[5-[2-(3,5-dimethoxyphenyl)ethyl]-2h-pyrazol-3-yl]-4-[(3r,5s)-3,5-dimethylpiperazin-1-yl]benzamide
US11498903B2 (en) 2017-08-17 2022-11-15 Bristol-Myers Squibb Company 2-(1,1′-biphenyl)-1H-benzodimidazole derivatives and related compounds as apelin and APJ agonists for treating cardiovascular diseases
WO2020183011A1 (en) 2019-03-14 2020-09-17 Institut Curie Htr1d inhibitors and uses thereof in the treatment of cancer
PL4225753T3 (pl) * 2020-10-08 2024-11-18 Leukos Biotech, S.L. Silne i selektywne związki jako modulatory receptora serotoniny 1b

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE204262T1 (de) * 1991-09-18 2001-09-15 Glaxo Group Ltd Benzanilidderivate als 5-ht1d-antagonisten

Also Published As

Publication number Publication date
WO1994015920A1 (en) 1994-07-21
AU5815594A (en) 1994-08-15
CN1094037A (zh) 1994-10-26
IL108218A0 (en) 1994-04-12

Similar Documents

Publication Publication Date Title
DK0598561T3 (enrdf_load_stackoverflow)
DK0613608T3 (enrdf_load_stackoverflow)
DK0553875T3 (enrdf_load_stackoverflow)
TW240217B (enrdf_load_stackoverflow)
DK0630289T3 (enrdf_load_stackoverflow)
DK109593A (enrdf_load_stackoverflow)
DK0644844T3 (enrdf_load_stackoverflow)
DK0576346T3 (enrdf_load_stackoverflow)
DK0574087T3 (enrdf_load_stackoverflow)
BR9207065A (enrdf_load_stackoverflow)
DK0581129T3 (enrdf_load_stackoverflow)
DK113692D0 (enrdf_load_stackoverflow)
DK0571172T3 (enrdf_load_stackoverflow)
AU2098792A (enrdf_load_stackoverflow)
AU1933792A (enrdf_load_stackoverflow)
AU634138B1 (enrdf_load_stackoverflow)
AU1610792A (enrdf_load_stackoverflow)
AU1707592A (enrdf_load_stackoverflow)
AU1737992A (enrdf_load_stackoverflow)
AU1803592A (enrdf_load_stackoverflow)
AU1812892A (enrdf_load_stackoverflow)
AU1844392A (enrdf_load_stackoverflow)
AU1849392A (enrdf_load_stackoverflow)
AU1862992A (enrdf_load_stackoverflow)
AU1281292A (enrdf_load_stackoverflow)